Director, MIT Koch Institute for Integrative Cancer Research
Dr. Jacks is the Director of the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. He is also Professor of Biology at MIT and an Investigator of the Howard Hughes Medical Institute. His graduate thesis was performed with Harold Varmus at the University of California, San Francisco, and he was a postdoctoral fellow with Robert Weinberg at the Whitehead Institute at MIT. Dr. Jacks joined the faculty at MIT in 1992. He has pioneered the use of gene-targeting technology in the mouse to study cancer-associated genes and to construct mouse models of many human cancer types. His laboratory has made seminal contributions to the construction of novel mouse models of human cancer and to the understanding of the effects of mutations of several tumor suppressor genes on tumor development, normal development and other cellular processes, including apoptosis, cell cycle control, intracellular signaling and cell migration. Dr. Jacks served on the Board of Scientific Advisors of the National Cancer Institute (NCI) and the Board of Directors of the American Association of Cancer Research (AACR). Dr. Jacks was a Merck Fellow of the Helen Hay Whitney Foundation, a Markey Scholar and a Searle Scholar. In recognition to his contribution to our understanding of cancer genetics, he has received the AACR Outstanding Achievement Award, the Amgen Award from the American Society of Biochemistry and Molecular Biology, and the Paul Marks Prize for Cancer Research. He was elected to the National Academy of Sciences as well as the Academy’s Institute of Medicine in 2009.
Dr. Jacks received his B.A. from Harvard College, where he graduated magna cum laude with highest honors in biology in 1983. He received his Ph.D. from the University of California, San Francisco in 1988.